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Background: Previous experimental studies concluded that stem cells (SC) may exert their beneficial effects on the
ischemic heart by paracrine activation of antiapoptotic pathways. In order to identify potential cardioprotective
mediators, we performed a systematic analysis of the differential gene expression of hematopoietic SC after
coculture with cardiomyocytes (CM).
Methods: After 48 h of coculture with neonatal rat ventricular CM (NRVCM), two consecutive cell sorting steps
generated a highly purified population of conditioned murine hematopoietic SC (>99%). Next, a genome-wide
microarray analysis of cocultured vs. monocultured hematopoietic SC derived from three independent experiments
was performed. The analysis of differentially expressed genes was focused on products that are secretable and/or
membrane-bound and potentially involved in antiapoptotic signalling.
Results: We found CCL-12, Macrophage Inhibitory Factor, Fibronectin and connexin 40 significantly upregulated in
our coculture model. An ELISA of cell culture supernatants was performed to confirm secretion of candidate genes
and showed that coculture supernatants revealed markedly higher CCL-12 concentrations. Moreover, we stimulated
NRVCM with concentrated coculture supernatants which resulted in a significant reduction of apoptosis compared
to monoculture-derived supernatant. Mechanistically, NRVCMs stimulated with coculture supernatants showed a
higher level of AKT-phosphorylation, consistent with enhanced antiapoptotic signaling.
Conclusion: In summary, our results show that the interaction between hematopoietic SC and NRVCM led to a
modified gene expression and induction of antiapoptotic pathways. These findings may thus at least in part explain
the cardioprotective effects of hematopoietic SC.
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Despite major advances in the treatment of coronary ar-
tery disease (CAD), acute myocardial infarction remains
a major cause of death worldwide. In fact, the acute loss
of blood supply potentially leads to apoptosis or necrosis
of cardiomyocytes (CM) served by the infarct related ar-
tery resulting in ischemic cardiomyopathy and congestive* Correspondence: norbert.frey@uksh.de
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distribution, and reproduction in any mediumheart failure. In the past the postmitotic heart had been
considered a terminal differentiated organ unable to re-
place a significant loss of tissue such as that after an
acute infarction [1]. This dogma has been challenged by
the recent discovery of resident cardiac stem cells (SC)
and the demonstration of hematopoietic SC that can
home to the heart and transdifferentiate into cardiomyo-
cytes [2,3]. These astonishing findings have led to the hy-
pothesis that SC could be used for regeneration of
infarcted myocardial tissue.
Therefore numerous studies have examined a potential
therapeutic effect of bone marrow derived SC on myo-
cardial function and regeneration after experimentaltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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these studies provided evidence for extensive myocardial
regeneration after cellular cardiomyoplasty [5], others
found no hematopoietic SC that had actually transdiffer-
entiated into CM [6,7]. Yet, regardless of the variable
effects on cardiac regeneration, virtually all of these stud-
ies found a significant improvement of cardiac function
after cellular therapy. It is now generally accepted that
SC therapy can favourably affect cardiac remodelling
after myocardial infarction, although the scientific basis
of this effect still remains to be elucidated.
Recent studies hypothesized that SC may exert their
beneficial influence on cardiac repair by paracrine action
on apoptosis or angiogenesis. It has been repeatedly
shown that various SC types can produce and secrete a
broad variety of cytokines, chemokines and growth fac-
tors that may be involved in cardiac repair [8-11].
On the basis of these experimental findings we postu-
lated that the direct interaction of hematopoietic SCs with
CM results in an upregulation of cardioprotective factors
that can be secreted by hematopoietic SC and promote
survival in cardiomyocytes. In order to identify interesting
candidate genes, we performed a systematic analysis of the
differential gene expression of hematopoietic SC after
coculture with NRVCM with special emphasis on gene
products involved in antiapoptotic signalling.Materials and methods
Animals
All experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals pub-
lished by US National Institutes of Health. The animal
study protocols were revised and approved by the Insti-
tutional Committee for the Ethics of Animal Care and
Treatment.Isolation and culture of neonatal rat ventricular
cardiomyocytes (NRVCM)
1–2 days old Wistar rats (Charles River, Sulzfeld, Ger-
many) were decapitized and hearts were harvested and
minced in ADS. Subsequently, up to six digestion steps
were carried out with pancreatin (Sigma, Munich, Ger-
many, 0.6 mg/ml) and collagenase type II (Worthington,
0.5 mg/ml) in sterile ADS buffer containing 120 mmol/l
NaCl, 20 mmol/l HEPES, 8 mmol/l NaH2PO4, 6 mmol/l
glucose, 5 mmol/l KCl, 0.8 mmol/l MgSO4, pH 7.4.
NRVCM were purified from contaminating fibroblasts
using a Percoll (Amersham, Germany) gradient centrifu-
gation step. Finally, NRVCMs were resuspended and
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% FCS, penicillin/streptomycin
and L-glutamine (all from PAA, Linz, Austria) [12,13].Isolation, purification and labelling of hematopoietic SC
Isolation, purification and labelling of hematopoietic
(lin-/c-kit+) SC were performed as described previously
[14,15] with the magnetic-activated cell sorting (MACS)-
kit from Miltenyi Biotech according to the manufac-
turer´s protocol. Briefly, C57Bl/6 mice were cervically
dislocated. Shortly thereafter tibias and femurs were col-
lected and flushed with phosphate-buffered solution
(PBS) containing 2% FCS. To remove cell clumps, crude
bone marrow was filtered through a 30 μm nylon mesh
(Miltenyi Biotech). For the purpose of depleting mature
blood cells such as T cells, B cells, monocytes/macro-
phages, granulocytes, erythrocytes as well as their
commited precursors, bone marrow cells were incubated
with a “cocktail” of biotinylated antibodies against a
panel of “lineage” (lin) antigens, including CD5, CD45R
(B220), CD11b, Anti-Gr-1 (Ly-6 G/C), 7–4 and Ter-119
(Lineage Cell Depletion Kit, Miltenyi Biotech). After
addition of anti-biotin microbeads, lin-positive cells were
separated using a magnetic column. Enrichment of the
lin-negative cells for a subpool of cells expressing the SC
marker c-kit/CD117 was performed by application of
CD117 microbeads (Miltenyi Biotech). The purity of the
separated cells was assessed by fluorescence-activated
cell sorting (FACS) using a phycoerythrin labelled anti-
body against CD 117 (Pharmingen). Integrity and via-
bility of purified lin-/c-kit + cells was confirmed by
propidium iodide (PI) (Sigma) staining. In order to be
able to detect and separate hematopoietic SC after cul-
ture with neonatal rat ventricular cardiac myocytes,
lin-/c-kit + cells were labelled with the green fluores-
cent “cell tracker” carboxyfluorescein diacetate succini-
mydil ester (CFDA) (TefLabs). Lin-/c-kit + stem cells
were therefore incubated for 30 min at 37°C with
5 μg/ml CFDA per 106 cells. The staining process was
concluded with two washing steps to assure clearance
of any unbound CFDA.
Coculture and separation of NRVCMs and Lin-/c-kit + stem
cells
The main objective of this study was to analyze the in-
fluence of a direct interaction with NRVCM on the gene
expression profile of hematopoietic SC. Therefore, a
coculture system of NRVCM with hematopoietic SC was
established as follows: NRVCMs were isolated from
whole hearts of 1–2 days old Wistar rats, resuspended
and cultured at a density of 2x106 cells per well in an
uncoated six well plate. After 48 h, hematopoietic SC
were separated from whole bone marrow of C57Bl/6
mice and added at a density of 0.5x106 cells per well
resulting in a ratio of NRVCM to lin-/c-kit + stem cells
of 4:1. Cell culture conditions remained unchanged at
37°C and 5% CO2 at all times. After 48 h the coculture
was stopped and the supernatant removed, immediately
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ther analysis. Next, remaining cells were washed twice
with PBS and dissolved using a Trypsin-EDTA solution
(0.25% (w/v), Invitrogen/GIBCO). Conditioned SC and
NRVCM were then separated by two consecutive cell
sorting steps using a FACS-Vantage SE flow cytometry
system running CellQuest software (BD). Reliable dis-
crimination of hematopoietic SC and NRVCM was
ensured utilizing both CFDA staining and different
forward-scatter and side-scatter signals. Viability and in-
tegrity of the cells was confirmed by staining with propi-
dium iodide (Sigma).
In order to be able to test the importance of direct cell-
cell interaction between NRVCM and hematopoietic SC,
conditioned cells were compared to identically treated
lin-/c-kit + control cells that were held in a monoculture
at a density of 2.5*106 cells per well in uncoated six well
plates. After 48 h, cells were washed twice with PBS and
dissolved using a Trypsin-EDTA solution (0.25% (w/v),
Invitrogen/GIBCO). Monocultured SC were also sorted
twice with FACS before being used for subsequent
experiments. Viability and integrity of monocultured
cells was again confirmed by staining with propidium
iodide (Sigma).
Further processing of conditioned SC, NRVCM and
supernatants is described in more detail in the Add-
itional file 1: Methods section. This includes the experi-
mental procedures of RNA isolation and purification,
ELISA assays, the detection of apoptotic NRVCM as well
as the stimulation of NRVCM with concentrated condi-
tioned media and immunoblotting. Since most of the
study results refer to analysis of the genetic profile of
hematopoietic SC, we decided to describe the process of
microarray hybridization and microarray data analyses
as well as real-time PCR analyses of gene expression in
more detail in the upcoming paragraphs.Probe labeling and Illumina sentrix BeadChip array
hybridization
Biotin-labeled cRNA samples for hybridization on Illu-
mina Mouse Sentrix-6 BeadChip arrays (Illumina, Inc.)
were prepared according to Illumina’s recommended
sample labeling procedure based on the modified Eber-
wine protocol [16]. In brief, 250 ng total RNA was used
for complementary DNA (cDNA) synthesis, followed
by an amplification/labeling step (in vitro transcription)
to synthesize biotin-labeled cRNA according to the
MessageAmp II aRNA Amplification kit (Ambion, Inc.,
Austin, TX). Biotin-16-UTP was purchased from Roche
Applied Science, Penzberg, Germany. The cRNA was
column purified according to TotalPrep RNA Amplifi-
cation Kit, and eluted in 60 μl of water. cRNA Quality
was checked using the RNA Nano Chip Assay on anAgilent 2100 Bioanalyzer and spectrophotometrically
quantified (NanoDrop).
Hybridization was performed at 58°C in GEX-HCB
buffer (Illumina Inc.) at a concentration of 50 ng cRNA/
μl and unsealed in a wet chamber for 20 h. Spike-in con-
trols for low, medium and highly abundant RNAs were
added, as well as mismatch control and biotinylation
control oligonucleotides. Microarrays were washed twice
in E1BC buffer (Illumina) at room temperature for
5 min. After blocking for 5 min in 4 ml of 1% (wt/vol)
Casein in phosphate buffered saline, Hammarsten grade
(Pierce Biotechnology, Inc., Rockford, IL), array signals
were developed by a 10-min incubation in 2 ml of 1 μg/ml
Cy3-streptavidin (Amersham Biosciences, Buckingham-
shire, UK) solution and 1% blocking solution. After a
final wash in E1BC, the arrays were dried and scanned.
Scanning and data analysis
Microarray scanning was done using a Beadstation array
scanner. Settings were adjusted to a scaling factor of 1
and PMT settings at 430. Data extraction was done for
all beads individually, and outliers were removed when
MAD (median absolute deviation) was >2.5. All
remaining data points were used for the calculation of
the mean average signal for a given probe, and the
standard deviation for each probe was calculated. Array
data were normalized using a quartile-normalization al-
gorithm. To select differentially expressed trancripts, an
empirical Bayes analysis was carried out. Transcripts
were selected as differentially expressed with p-values
<0.05 and corrected for multiple testing by a Benjamini
& Hochberg algorithm [17]. Gene expression was visua-
lized by scatterplots and heatmaps. Data analysis was
performed with R (version 2.7.2) and Bioconductor (ver-
sion 2.0.1) using the packages beadarray (version 1.8.0)
and limma (version 2.14.7). Differentially expressed tran-
scripts were further classified by cellular location of the
corresponding proteins using the LOCATE subcellular
localization database (http://locate.imb.uq.edu.au/) and
according to their function using PANTHER Classifica-
tion System (http://www.pantherdb.org/).
Quantitative real-time PCR analysis of gene expression
Real-time PCR (RT-PCR) was used to further validate
data generated in the microarray analysis and performed
as follows: 100 ng of DNase-digested total RNA of each
condition was transcribed to first strand cDNA with the
Transcriptor first strand cDNA synthesis kit (Roche,
Germany). Reaction conditions were set as recom-
mended by the supplier. Real time PCR primers (MWG
Biotech) were designed assisted by the Primer 3 software
(http://primer3.sourceforge.net/). Targets were normal-
ized using oligonucleotide primers for GAPDH as an
internal standard. The resulting amplicons contained
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Sequence Detection System (Perkin Elmer Applied Bio-
systems) and the Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen) were used for performing
real-time PCR from reverse transcribed cDNA samples
following the manufacturer’s instructions. Specificity of
the reactions was checked by melting curve analysis
and by verifying the correct size of the product on a
2% agarose gel. Each PCR amplification was carried
out in duplicate wells, using the following conditions:
2 min at 50°C, 2 min at 95°C, followed by a total of
40 temperature cycles (15 s at 95°C and 30 s at 60°C).
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis
was carried out with Students-t-Test, if not noted differ-
ently. P< 0.05 was considered statistically significant.
Results
Generation of a highly purified population of
hematopoietic SC after coculture with NRVCM
Hematopoietic SC were isolated from male C57BL/6
mice by magnetic cell sorting, typically resulting in a
yield of 1.1–1.4 x 108 bone marrow cells per dissected
mouse. After the separation process, approximately
0.9–1.2 x 106 hematopoietic SC were obtained, corre-
sponding to ~1% of all isolated bone marrow cells.
FACS-analyses were performed to check for purity and
viability of the separated stem cells. NRVCM wereFigure 1 shows the experimental setup. After 48 h of coculture with NR
conditioned murine hematopoietic SC that were used for RNA isolation an
V and tested for apoptosis by FACS. Finally, coculture supernatants were coprepared from 1–2 days old Wistar Rats using a per-
coll gradient centrifugation.
In order to elucidate potential molecular mechanisms
of SC mediated cardiac regeneration and repair, we
established a coculture system of CFDA labeled
hematopoietic SC and NRVCM at a ratio of 1:4 per well
(Figure 1). After 48 h of coculture, cells were separated
by FACS (Figure 2A). Two consecutive cell-sorting steps
enabled us to generate a highly purified (purity >99.5%)
population of hematopoietic SC that were stimulated by
NRVCM for 48 h (Figure 2B). These cells were subse-
quently used for further microarray analyses and com-
pared to identically treated hematopoietic SC that were
held in a monoculture for 48 h.
Microarray analysis of hematopoietic SC after coculture
with NRVCM
We hypothesized that the direct interaction of
hematopoietic SC with NRVCM may lead to an upregula-
tion of cardioprotective genes in SC. Therefore we per-
formed a genome-wide transcriptome microarray analysis
of cocultured versus monocultured hematopoietic SC. We
used RNA of three independent coculture and three
monoculture experiments, respectively. Bayes analysis of
the raw data revealed 3014 differentially regulated tran-
scripts. Genes were considered differentially regulated,
when up- or downregulation exceeded 50%. Regulation
status in the scatter blot is colour coded. Upregulated
genes appear red, downregulated genes blue and genesVCM two cell sorting steps generated a highly purified population of
d microarray analysis. Conditioned NRVCM were labeled with Annexin
ncentrated and used for ELISA and stimulation of NRVCM.
Figure 2 illustrates the FACS analysis of CFDA labeled cocultured hematopoietic SC. (a) Here we show the coculture prior to separation.
After two consecutive cell sorting steps a highly purified population of hematopoietic SC with a purity >99.5% were generated and used for
further experiments (b).
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dots. 1500 were significantly (p< 0.05) and more than 1.5
fold upregulated (Figure 3A), whereas 1514 were signifi-
cantly downregulated (less than 0.5 fold). Next, resulting
data were normalized and displayed in heat maps, reveal-
ing highly reproducible results within groups and a low
variance between microarray hybridizations (Figure 3B).
We hypothesized that the close interaction of
hematopoietic SC with NRVCM may lead to differential
regulation of genes that promote survival of NRVCM viaFigure 3 displays the microarray analysis of cocultured hematopoieti
differentially regulated transcripts in cocultured hematopoietic SC plotted a
upregulation, blue dots downregulation. (b) Heat map displaying 3014 diff
blue colour downregulation.inhibition of apoptosis. Therefore, further processing of
data generated from the microarray analysis focused on
upregulated genes with secretable products that interfere
with apoptotic pathways. We used two different databases
(LOCATE, PANTHER) to identify candidate genes that
met these criteria. Thereby, we were able to restrict our
list to 8 genes. Specifically, CXCL 1, CCL 6, CCL 12,
EGFL 7, FN 1, GJA 5, MIF and TIMP were shown to be
not only significantly upregulated in our microarray ana-
lysis but also fulfilled our above mentioned prerequisites.c SC. (a) Scatter plots showing the log ratios of the means of
gainst monocultured hematopoietic SC. Red dots represent
erentially regulated transcripts. Red colour represents upregulation,
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cussed in this publication have been deposited in NCBI's
Gene Expression Omnibus [18] and are accessible through
GEO Series accession number GSE21098 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi? token= vvyhramgioy-
kypi&acc =GSE21098). Interestingly, we found no evi-
dence for any transdifferentiation of hematopoietic SC
towards a cardiac lineage. Consistently, early cardiac-
specific transcripts like Nkx2-5, MEF2C, GATA4, markers
of the primary heart field like Tbox5 and Hand1 or sec-
ondary heart field such as Isl1 and Fgf10, were not found
to be differentially expressed, neither were later cardiac
specific transcripts like alpha-MHC, Troponin-T, alpha-
actinin, and Troponin-I. Flk-1, which is known to be a
marker for multilineage mesoderm progenitor cells, was
not differentially expressed as well. In addition, these find-
ings confirm the high purity of our cell separation, result-
ing in no measurable contamination of hematopoietic SC
with NRVCM RNA.
Moreover, our number of differentially regulated genes
in the microarray analysis was rather high. We have
therefore added a list of genes that had an adjusted
p-value of <0.05 and an upregulation of more than
1.5-fold. Next, we used DAVID Bioinformatics Ressources
v6.7 to functionally annotate our transcripts via Gene
Ontology [19,20]. We selected transcripts with the fol-
lowing Gene Ontology terms for further analysis:
Apoptosis, Angiogenesis, Proliferation, Heart develop-
ment, Immune response, Cell migration, Cell growth.
These genes were classified according to their bio-
logical function. This list is added to the manuscript
as Additional file 2: Table S1.
Confirmation of microarray data by real-time PCR
We used quantitative Real-Time PCR to verify differential
expression of selected genes in cocultured and monocul-
tured hematopoietic SC. We primarily focused on genes
with potentially secretable and antiapoptotic products for
which an upregulation was predicted by our microarrayTable 1 Differentially regulated antiapoptotic genes in
cocultured hematopoietic SC detected by microarray
analyses
Symbol Gene-Name Fold-Change p-Value
CCL6 Chemokine (C-C motif) ligand 6 3.04 0.01
CCL12 Chemokine (C-C motif) ligand 12 4.65 0.029
CXCL1 Chemokine (C-X-C motif) ligand 1 4.42 0.049
EGFL7 EGF-like domain 7, transcript variant c 4.18 0.002
FN1 Fibronectin 1 5.16 0.017
GJA5 Gap Junction membrane
channel protein alpha 5
1.57 0.001
MIF Macrophage migration inhibitory factor 2.82 0.004
TIMP Tissue inhibitor of metalloproteinase 1.44 0.004data. Thereby we were able to show that coculture of
hematopoietic SC with NRVCM for 48 h leads to an 14.8
fold upregulation of the chemokine (C-C motif) ligand 12
(CCL12) (p< 0.05), whereas expression of the gap junc-
tion membrane channel protein alpha 5 (GJA5, Connexin
40) was 4.5 fold induced (p< 0.05 versus control). Fur-
thermore, real-time data revealed a significant 1.8 fold
upregulation of the macrophage migration inhibitory fac-
tor and a 5.6-fold overexpression of Fibronectin in condi-
tioned hematopoietic SC (p< 0.001) (Figure 4A). In
contrast, we could not confirm significant differential ex-
pression of CXCL1, CCL 6, EGFL 7 or TIMP by real-time
PCR, although the trend of their differential expression
was consistent with the microarray data (p> 0.05).
Antiapoptotic proteins are elevated in supernatants of
cocultured hematopoietic SC
We initially hypothesized that cocultured hematopoietic
SC express antiapoptotic proteins that may exert benefi-
cial effects on NRVCM survival via a paracrine mechan-
ism. We therefore collected and analyzed supernatants of
several coculture experiments for increased levels of pro-
teins identified in the microarray experiments. We mea-
sured the concentration of CCL12 in concentrated
supernatants of three independent mono- and coculture
experiments by ELISA. Thereby we were able to show that
the CCL12 concentration is indeed significantly elevated
in concentrated supernatants collected under coculture
conditions when compared to monoculture experiments
(21 pg/ml vs. 3,3 pg/ml; p< 0.05) (Figure 4B).
Coculture with hematopoietic SC leads to inhibition of
NRVCM apoptosis
Since our findings demonstrated that coculture of
hematopoietic SC with NRVCM leads to an overexpres-
sion of secretable antiapoptotic proteins in SC, we were
next asking whether these findings also translated into a
reduced apoptosis rate in cocultured NRVCM. In order
to address this question we repeated our coculture
experiments with PI-/Annexin-V-staining. After 48 h of
coculture and monoculture, we used APC-conjugated
Annexin-V and PI to identify the fraction of apoptotic
cells (Annexin V positive, PI negative) within the popu-
lation of cocultured NRVCM (CFDA-/APC+/PI-) in
comparison to identically stained NRVCM in monocul-
ture. Indeed, coculture with hematopoietic SC cuts the
number of apoptotic NRVCM by half when compared to
monocultured NRVCM (12% vs. 24%; p< 0.05; n = 5)
(Figure 5).
Antiapoptotic effects are mediated via activation of the
AKT/PKB pathway
Finally, we sought to begin to investigate the underlying
molecular mechanism that mediates antiapoptotic signals
Figure 4 demonstrates that coculture with NRVCM leads to overexpression of antiapoptotic factors in hematopoietic SC. (a) CCL-12, FN-
1, GJA-5 and MIF mRNAs are upregulated in cocultured hematopoietic SC (n = 8). Levels of significance *p< 0.05, ** p< 0.01, *** p< 0.001.
(b) ELISA from concentrated cell culture supernatants show higher CCL-12 levels in coculture supernatants compared to monoculture
supernatants (n = 3). Level of significance *p< 0.05.
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shown before that CCL 12, FN-1 and MIF can trigger
phosphorylation of the antiapoptotic protein AKT via ac-
tivation of PI3K [21-23]. We therefore tested the hypoth-
esis that inhibition of apoptosis in cocultured NRVCM is
related to an increased phosphorylation of AKT induced
by factors secreted from hematopoietic SC in a paracrine
manner. Hence, we used concentrated cell culture super-
natants of several NRVCM/hematopoietic SC coculture
and hematopoietic SC monoculture experiments to
stimulate NRVCM that were held in a monoculture for
48 h. Densitometry of western-blots was utilized to com-
pare the activation of selected signal transduction cas-
cades. We found the anti-apoptotic AKT/PKB-pathway
being significantly higher activated (ratio of Phospo-
Akt473 to Akt) after stimulation with coculture medium
compared to monoculture medium (5.2 vs. 3.2 arbitrary
units, p< 0.01) (Figure 6). These findings suggest thatsurvival of NRVCM that are held in a coculture with
hematopoietic SC is improved by paracrine activation of
the AKT/PKB signal transduction cascade.
Discussion
Despite the fascinating idea of myocardial regeneration
by undifferentiated precursor cells, the observed clinical
effects of cellular cardiomyoplasty so far are rather mod-
est and the underlying molecular mechanisms still re-
main unclear. One of the proposed mechanisms is the
secretion of paracrine factors by SC that can modify car-
dioprotective signaling. The identification of these cyto-
kines would be of high clinical relevance, since it may
offer the possibility to establish new therapeutic options
after myocardial infarction.
We thus hypothesized that a systematic analysis of the
differential gene expression of hematopoietic SC after
coculture with NRVCM may lead to the recognition
Figure 5 confirms that coculture with hematopoietic SC inhibits apoptosis in NRVCM. NRVCM were stained with Annexin-V-/
Propidiumiodid and analyzed for apoptosis after coculture (a) or monoculture (b). Analysis of five experiments reveal significant less apoptotis in
cocultured NRVCM (Annexin-V-positive, PI-negative cells) (c). All values are expressed as means +/− SEM. Level of significance: *p< 0.05.
Figure 6 reveals that antiapoptotic effects are mediated in an
AKT dependent manner. Western-Blot analysis shows that
stimulation with concentrated coculture medium (n = 3) leads to
higher AKT phosphorylation in NRVCM compared to stimulation
with concentrated monoculture medium (n= 3) (a). Densitometric
analysis reconfirms the significant difference in AKT phosphorylation
(b). All values are expressed as means +/− SEM. Level of significance:
*p< 0.05, **p< 0.01.
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cell-cell interaction with NRVCM indeed results in an
upregulation of secretable antiapoptotic proteins in
hematopoietic SC which in turn improved NRVCM
survival by paracrine pathways.
We used a genomic approach to identify genes overex-
pressed in hematopoietic SC after coculture with
NRVCM. In the search of factors with therapeutic po-
tential after myocardial infarction we restricted our ana-
lysis to genes that are not only significantly upregulated
but also encoded for secreted or membrane-bound pro-
teins. Moreover, we finally selected proteins that are also
known to interfere with antiapoptotic signaling. Using
such a systematic approach we were able to narrow
down an initial list of 3014 differentially regulated genes
to 8 genes. Biological validation of our microarray data
by Real-Time PCR confirmed significant results for
CCL-12, MIF, FN-1 and GJA-5, while there was only a
strong trend towards upregulation for CXCL1, CCL 6,
EGFL 7 and TIMP. Hence, our results demonstrate that
coculture with NRVCM leads to a change in the secre-
tome of hematopoietic SC.
Chemokine ligand 12 (CCL-12) is a small cytokine
belonging to the C-C motif chemokine family. It is also
known as monocyte chemotactic protein 5 (MCP-5) or
as MCP-1 related chemokine. CCL-12 has been previ-
ously shown to be constitutively expressed in lymph
nodes and thymus under basal conditions [24,25]. CCR2
is the receptor for CCL-12, which is not only expressed
on monocytes and activated lymphocytes, but can also
be found on cardiomyocytes [26]. Several experimental
studies in rat neurons and murine lymphocytes indicated
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phosphorylation of AKT [27]. Thus, the increased phos-
phorylation of AKT observed in cocultured NRVCM
may at least in part be explained by the paracrine action
of CCL-12.
Another interesting candidate found upregulated in
our experiments is the macrophage migration inhibitory
factor (MIF). MIF is a pleiotropic cytokine which regu-
lates the release of other pro-inflammatory cytokines
and therefore is of great importance in mediating in-
flammatory responses [28]. MIF is known to be
expressed and released upon stimulation from pre-
formed storage pools by several cell types, including
macrophages/monocytes, vascular smooth muscle cells
and cardiomyocytes [29-31]. It has been shown that sig-
nal transduction of extracellular MIF involves a receptor
tyrosine kinase (RTK)-like complex [32], promoting the
activation of the PI3K/Akt pathway and cellular survival
[22]. The biological relevance of this pathway has also
been shown in the heart. Miller et al. demonstrated that
MIF protects the rat heart from ischemia-reperfusion in-
jury by stimulation of AMP-activated protein kinase
(AMPK) in an autocrine manner [33]. Taken together,
our results indicate that coculture of hematopoietic SC
with NRVCM lead to an enhanced secretion of MIF by
SC which may in turn protect NRVCM from apoptosis
via phosphorylation of Akt in a paracrine manner.
Furthermore, it has become increasingly clear that
interactions between extracellular matrix proteins and
integrins not only mediate cell adhesion but also generate
signals that play an important role in promoting cell sur-
vival [34]. Of note, Fibronectin (FN), one of the extracel-
lular adhesive glycoproteins involved in these processes,
was also found to be differentially regulated in our cocul-
ture experiments. FN is considered to provide survival
signals for many cell types through its RGD motif that
predominantly interacts with ß1-integrins, including α3β1
and α5β1 integrins [35]. The latter integrin was identified
as an important regulator of apoptosis and is also
expressed in cardiomyocytes [36-38]. Moreover, it has
been repeatedly demonstrated that downstream signaling
of α5β1 integrin involves a PI3K-dependent phosphoryl-
ation of AKT [23,39]. We therefore hypothesize that
coculture-induced overexpression of FN in hematopoietic
SC also contributes to the protection of NRVCM against
proapoptotic stimuli by an integrin mediated activation
of the PI3K/AKT pathway.
Finally, our results demonstrated that Gap junction
protein-5 alpha (GJA-5) is significantly upregulated in
hematopoietic SC after coculture with NRVCM. GJA-5,
which is also known as Connexin 40, plays an important
role in the formation of gap junctions that are clusters
of intercellular channels consisting of a hexameric as-
sembly of proteins. These gap junction channels can linkneighboring cells and thereby provide the molecular
framework of intercellular communication [40]. More-
over, it has been shown that in a variety of cells overex-
pression of Connexin 40 leads to increased resistance
against several types of injury including calcium over-
load and oxidative stress. Surprisingly, the protective ac-
tivity of connexin proteins was found to be independent
of gap junction channel function [41]. Our finding of
GJA-5 overexpression in conditioned SC may thus also
contribute to improved intercellular connections be-
tween cocultured cells and/or increased resistance
against cellular injury.
Thus, at least to our knowledge, we here demonstrate
for the first time a systematic analysis of the differential
gene expression in adult hematopoietic SC modified by a
coculture with NRVCM. Our results show that a direct
interaction of hematopoietic SC with NRVCM leads to
an overexpression of antiapoptotic proteins in adult
hematopoietic SC which may improve NRVCM survival
in a paracrine manner. These data are in line with previ-
ous reports. The Dzau group showed that cell culture
medium conditioned by hypoxic mesenchymal SC that
were transduced with an Akt-1 overexpressing retrovirus
reduced apoptosis and necrosis in isolated NRVCM [42].
As the putative underlying mechanism the same group
presented data that revealed upregulation of potentially
cytoprotective molecules such as VEGF, FGF, HGF or
IGF in hypoxic and genetically modified mesenchymal
SC [11]. Other groups have confirmed the paracrine
effects of bone marrow derived SC on ischemic CM
[43,44]. Uemura et al. demonstrated that hypoxia
induced apoptosis of CM could be reduced by coculture
with bone marrow derived mesenchymal SC. Since
VEGF, bFGF, IGF and SDF-1 were found in the super-
natant of mesenchymal SC culture, this group also
argued for a paracrine mediated effect [45]. Similar
results were also reported in a clinical setting. Korf-
Klingebiel et al. used blood samples from 15 patients
with acute myocardial infarction and isolated unselected
nucleated bone marrow cells (BMSCs) and peripheral
blood leukocytes (PBL). Cells were cultured to obtain
conditioned supernatants. Cell culture medium of both
cell types synergistically induced angiogenesis in a mouse
aortic ring assay and protected rat CM from cell death
induced by ischaemia followed by reperfusion [46].
How do our results fit into this context? We believe
that our experimental approach is closer to the clinical
setting, where bone marrow cells may directly interact
with CM. While the above cited papers examined the
generation of cytoprotective factors in various types of
SC under monoculture conditions, we developed a cocul-
ture model that gave us the possibility to systematically
analyze the differential gene expression in hematopoietic
SC modified by direct interaction with NRVCM. We and
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cardially injected hematopoietic SC are to some extent
retained in the ischemic myocardium [14,47]. Based
on the results presented in this study we propose that
a direct interaction with NRVCM induces the expres-
sion of antiapoptotic proteins in myocardially retained
hematopoietic SC which in turn may contribute to the
beneficial effects of cellular cardiomyoplasty. Of note,
we also found several genes differentially regulated that
play a role in other potentially cardioprotective path-
ways such as angiogenesis and immune response. Thus,
it seems likely that in vivo additional mechanisms con-
tribute to the effects of hematopoetic stem cells.
Some limitations of our work need further appreci-
ation. For several reasons we preferred a genomic ap-
proach to systematically analyze the effects of coculture
on adult hematopoietic SC. Compared to a proteomic
approach a genomic approach is technically less demand-
ing, more comprehensive and offers the possibility to de-
tect new genes with previously unknown effects in SC
therapy. On the other hand, a genomic approach can
overlook important posttranscriptional events such as al-
ternative splicing. Furthermore, it was beyond the scope
of this study to analyze the therapeutic potentials of
novel cytoprotective factors. Further studies will be
needed to determine the therapeutic potentials of overex-
pressing factors such as CCL-12, MIF, FN or GJA-5. Fi-
nally, despite the high degree of purification of
hematopoetic stem cells in our experimental setting, we
cannot exclude that other cell types, e.g. macrophages,
also contribute to the observed effects.
Conclusion
In summary, we here present for the first time a com-
prehensive analysis of the gene expression program of
hematopoietic SC after coculture with NRVCM. Thereby
we were able to demonstrate that the direct interaction
of hematopoietic SC with NRVCM leads to an upregula-
tion of secretable and/or membrane bound antiapoptotic
proteins which in turn improve NRVCM survival in a
paracrine manner. Further studies will have to show
whether the use of single cytoprotective factors can
achieve similar results compared to cellular therapy after
myocardial infarction.
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